STALEVO 50 pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical	⤷ Get Started Free	2023-05-5H00538	⤷ Get Started Free
RR Scientific	⤷ Get Started Free	R6267804	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 2, 2025

Introduction

STALEVO 50 is a prescription medication primarily used to treat Parkinson's disease. It combines three active ingredients: levodopa, carbidopa, and entacapone. As a critical therapeutic agent, the supply chain of its active pharmaceutical ingredients (APIs) directly influences manufacturing stability, regulatory compliance, and market availability. This article explores the global sources of APIs for STALEVO 50, analyzing key suppliers, manufacturing trends, and industry considerations essential for stakeholders aiming to establish or evaluate reliable procurement channels.

Understanding the Composition of STALEVO 50

STALEVO 50 comprises:

Levodopa: The primary dopamine precursor restoring dopamine levels in the brain.
Carbidopa: An inhibitor of peripheral decarboxylase enzyme, enhancing levodopa bioavailability.
Entacapone: A COMT inhibitor, prolonging the effect of levodopa.

Each component's sourcing impacts overall drug quality, cost, and Supply Chain Security.

Global API Manufacturers for Levodopa

1. Major Suppliers of Levodopa

Levodopa's global supply is concentrated among a handful of established manufacturers, predominantly in China, India, and Europe.

Jiangsu Hengrui Medicine Co., Ltd. (China): A leading producer offering high-purity levodopa. Hengrui leverages advanced synthesis methods to meet international standards, including USP and EP specifications.
Hunan Zhongda Pharmaceutical Group (China): Supplies both bulk levodopa and intermediates, with consistent manufacturing quality and competitive pricing.
Kowax Pharmaceuticals (India): An emerging vendor providing generic levodopa APIs with compliance to global regulatory standards.
Bayer AG (Germany): Historically a pioneer in levodopa production, supplying high-quality APIs for global markets, though their focus has shifted toward proprietary formulations.

2. Manufacturing Trends and Considerations

Levodopa APIs are predominantly synthesized via chemical processes involving aromatic compounds. The reliance on Chinese and Indian manufacturers continues due to cost advantages and scalable capacities. However, regulatory scrutiny and quality assurance procedures are critical when sourcing from these regions, emphasizing the importance of audits and certifications such as cGMP compliance.

Sources for Carbidopa API

1. Predominant Carbidopa Producers

Shanghai Shyndec Pharmaceutical Co., Ltd. (China): Offers high-purity carbidopa, aligning with pharmaceutical standards.
Sun Pharmaceutical Industries Ltd. (India): Supplies both generic and branded carbidopa API with extensive regulatory approvals.
Ningbo Universal Pharmaceutical Co., Ltd. (China): Recognized for consistent quality and supply chain reliability.

2. Industry Highlights

Carbidopa's synthesis involves complex aromatic amines and is sensitive to batch variability. Suppliers with robust quality controls and GMP certification are preferred. A notable trend involves vertical integration with levodopa producers, ensuring compatibility and traceability.

Sources for Entacapone API

1. Leading Entacapone API Manufacturers

Mingke Pharmaceutical Co., Ltd. (China): One of the primary suppliers, offering entacapone conforming to international standards.
LGM Pharma (USA): Specializes in high-quality APIs, including entacapone, with stringent quality assurance processes.
Jiangsu Nhwa Pharmaceutical Co., Ltd. (China): Provides pharmaceutical-grade entacapone API with extensive regulatory dossier support.

2. Industry Dynamics

Entacapone synthesis involves complex chemical pathways, with a significant manufacturing reliance on Chinese API producers. There is a rising demand for supply chain diversification to mitigate geopolitical risks and ensure continuous availability.

Regional Trends and Market Dynamics

China as a Major API Hub

China remains the dominant supplier for all components of STALEVO 50's API profile due to large-scale production, cost competitiveness, and ongoing capacity expansions. Chinese manufacturers frequently pursue cGMP certification to access Western markets, aligning with stricter regulatory standards.

India’s Growing Role

India's API industry is rising in prominence thanks to cost advantages and increased regulatory focus on quality. Several Indian companies meet international standards, offering a reliable alternative or supplement to Chinese sources.

Europe and the USA

European and American manufacturers generally serve niche markets with high-quality, compliant APIs but at higher costs. Limited capacity and higher regulatory thresholds often restrict their supply to specialized or small-volume needs.

Regulatory and Quality Considerations

Procurement of APIs for STALEVO 50 mandates compliance with strict regulatory standards, including:

Current Good Manufacturing Practices (cGMP): Ensuring product quality and safety.
Certifications: Such as ISO, WHO-GMP, and site-specific approvals from authorities like the FDA, EMA, or PMDA.
Documentation: Certificates of Analysis (CoA), Material Safety Data Sheets (MSDS), and regulatory dossiers.

Due to the critical nature of these APIs, partnerships with verified suppliers possessing strong regulatory track records are essential.

Supply Chain Security and Risk Mitigation

Dependence on specific regional sources introduces supply vulnerabilities. To mitigate risks, pharmaceutical companies often:

Diversify suppliers across regions.
Establish long-term contracts with multiple validated manufacturers.
Conduct periodic audits and inspections.
Maintain strategic inventories for buffer stock.

Conclusion

Reliable sourcing of APIs for STALEVO 50 hinges on purification standards, regulatory compliance, and geopolitical stability. The dominant suppliers include Chinese firms such as Jiangsu Hengrui and Mingke Pharmaceutical, Indian giants like Sun Pharma, and select Western manufacturers. Navigating this landscape involves balancing cost, quality, and supply security — vital considerations for manufacturers, regulators, and end-users.

Key Takeaways

Consolidated Supplier Base: Chinese and Indian manufacturers dominate API supply for STALEVO 50, emphasizing the need for rigorous supplier validation.
Regulatory Compliance Is Critical: Suppliers must comply with cGMP and possess relevant certifications to meet international requirements.
Supply Chain Diversification Prevents Disruptions: Engaging multiple sources across regions reduces geopolitical and quality risks.
Quality Assurance Is Non-Negotiable: Consistent high purity and documentation support manufacturing integrity.
Strategic Procurement Is Essential: Long-term partnerships and monitoring of industry trends ensure continuous API availability.

FAQs

1. Are Chinese API manufacturers for STALEVO 50 globally compliant?
Many leading Chinese API producers hold cGMP certifications and meet international quality standards, but due diligence and regular audits are essential before establishing partnerships.

2. What are the main challenges in sourcing APIs for Parkinson’s medications like STALEVO 50?
Challenges include regulatory compliance, ensuring product consistency, supply chain disruptions, and geopolitical risks.

3. How can manufacturers ensure the quality of imported APIs?
Through stringent supplier qualification processes, verifying certifications, conducting on-site audits, and reviewing Certificates of Analysis and regulatory dossiers.

4. Is there a growing trend toward sourcing APIs from India for Parkinson's treatments?
Yes, Indian API manufacturers are expanding their capacity with a focus on quality and regulatory compliance, increasingly serving global markets.

5. What factors should be considered when selecting an API supplier for high-demand medications?
Factors include quality certifications, manufacturing capacity, regulatory track records, supply reliability, pricing, and logistical considerations.

Sources

[1] U.S. Food and Drug Administration (FDA) database.
[2] European Medicines Agency (EMA) guidelines.
[3] Industry reports on API manufacturing trends (Pharmaceutical Technology, 2022).
[4] Company disclosures and regulatory filings from Jiangsu Hengrui and Mingke Pharmaceutical.
[5] Market analyses from IQVIA and Evaluated Market Research (2022).

Bulk Pharmaceutical API Sources for STALEVO 50